{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Pediatric&page=7",
    "query": {
      "condition": "Cancer Pediatric",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 1301,
    "total_pages": 131,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Pediatric&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer+Pediatric&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T11:36:59.756Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00923650",
      "title": "Informed Consent in Pediatric Cancer Trials",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Osteosarcoma",
        "Ewing's Sarcoma",
        "Neuroblastoma",
        "Brain Tumors",
        "Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 1,
      "start_date": "2008-12-09",
      "completion_date": "2010-02-02",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 2,
      "location_summary": "Bethesda, Maryland • Cleveland, Ohio",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00923650"
    },
    {
      "nct_id": "NCT04833582",
      "title": "A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Osteosarcoma"
      ],
      "interventions": [
        {
          "name": "Azenosertib",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2021-08-01",
      "completion_date": "2024-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Oakland, California • Santa Monica, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04833582"
    },
    {
      "nct_id": "NCT02793466",
      "title": "Durvalumab in Pediatric and Adolescent Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Lymphoma",
        "Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "Durvalumab; MEDI4736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Leo Mascarenhas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 15,
      "start_date": "2016-07",
      "completion_date": "2023-04-30",
      "has_results": false,
      "last_update_posted_date": "2023-09-22",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793466"
    },
    {
      "nct_id": "NCT00801346",
      "title": "Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fatigue",
        "Leukemia",
        "Long-term Effects Secondary to Cancer Therapy in Children"
      ],
      "interventions": [
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "metabolic assessment",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        },
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        },
        {
          "name": "fatigue assessment and management",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "1 Year to 20 Years"
      },
      "enrollment_count": 224,
      "start_date": "2008-11",
      "completion_date": "2016-04",
      "has_results": false,
      "last_update_posted_date": "2017-04-21",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 3,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00801346"
    },
    {
      "nct_id": "NCT05503797",
      "title": "A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cancer Harboring BRAF Alterations",
        "HGG",
        "LGG",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Plixorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fore Biotherapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 254,
      "start_date": "2023-02-21",
      "completion_date": "2028-12-28",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 30,
      "location_summary": "Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 23 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Westwood, Los Angeles",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05503797"
    },
    {
      "nct_id": "NCT02625480",
      "title": "Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia",
        "Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brexucabtagene Autoleucel (KTE-X19)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 95,
      "start_date": "2016-02-01",
      "completion_date": "2026-03-25",
      "has_results": false,
      "last_update_posted_date": "2026-04-09",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Orange, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02625480"
    },
    {
      "nct_id": "NCT06104488",
      "title": "A Study of Avutometinib for People With Solid Tumor Cancers",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Cancer",
        "CNS Tumors",
        "CNS Tumor, Adult",
        "CNS Tumor, Childhood",
        "MAP Kinase Family Gene Mutation",
        "NF1",
        "Plexiform Neurofibroma",
        "Low-grade Glioma",
        "Optic Pathway Gliomas",
        "Neuroblastoma",
        "Primary Brain Tumor",
        "Solid Tumor",
        "Solid Tumor, Adult",
        "Solid Carcinoma",
        "Central Nervous System Tumor"
      ],
      "interventions": [
        {
          "name": "Avutometinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "3 Years to 30 Years"
      },
      "enrollment_count": 3,
      "start_date": "2023-10-20",
      "completion_date": "2029-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • New York, New York",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06104488"
    },
    {
      "nct_id": "NCT00003241",
      "title": "Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "phenylacetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Texas Children's Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "1998-05",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003241"
    },
    {
      "nct_id": "NCT04276194",
      "title": "Vertebral Body Sparing Craniospinal Irradiation for Pediatric Patients With Cancer of the Central Nervous System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Malignant Central Nervous System Neoplasm"
      ],
      "interventions": [
        {
          "name": "Intensity-Modulated Proton Therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 10,
      "start_date": "2019-12-16",
      "completion_date": "2024-02-09",
      "has_results": false,
      "last_update_posted_date": "2024-03-21",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04276194"
    },
    {
      "nct_id": "NCT07551583",
      "title": "Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 15,
      "start_date": "2026-08-19",
      "completion_date": "2032-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-31",
      "last_synced_at": "2026-10-21T11:36:59.756Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07551583"
    }
  ]
}